FIELD: biotechnology.
SUBSTANCE: invention relates to stabilization of glucagon analogues in pharmaceutical formulations and can be used in medicine in treating hypoglycaemia. Disclosed are stable liquid aqueous pharmaceutical formulations for controlling blood glucose levels containing a glucagon analogue Hy-HSQGTFTSDYSKYLD-Aib-ARAEEFVKWLEST-OH or its pharmaceutically acceptable salt and a combination of excipients. TRIS, ACES and MES buffers and/or acetate, citrate or succinate buffers provide chemical stability of said glucagon analogue compositions at weakly acidic or neutral pH. Comparative analysis of degradation profiles has shown that these buffers provide higher stability compared to other tested buffer systems, such as histidine or phosphate, even if the compositions have the same pH, that is, the stability provided by the buffers is at least partially independent of their pH-modulating properties.
EFFECT: invention provides long-term stability of dasiglucagon in liquid form.
17 cl, 21 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL FORMULA CONTAINING HUMAN ANTI-TSLP ANTIBODY | 2016 |
|
RU2794148C2 |
| NEUROACTIVE STEROID SOLUTIONS AND METHODS FOR ADMINISTRATION | 2016 |
|
RU2803464C2 |
| ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PLASMINOGEN, AND USE THEREOF | 2015 |
|
RU2711989C2 |
| FSH STABILISATION | 2011 |
|
RU2574012C2 |
| COMPOSITION OF NEUREGULIN PREPARATION | 2014 |
|
RU2738158C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | 2014 |
|
RU2702345C2 |
| HUMAN INTERFERON-BETA VARIANT WITH DOUBLE MUTATION AND METHOD FOR IMPROVING STABILITY OF HUMAN INTERFERON-BETA VARIANT | 2021 |
|
RU2812047C1 |
| BUFFERS FOR STABILIZING LENTIVIRAL DRUGS | 2016 |
|
RU2747231C2 |
